What is the 13F Pro Quality Score for DSGN?

13F Pro ranks Design Therapeutics, Inc. (DSGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View DSGN's current score at https://13fpro.ai/research/DSGN (free sign-up required for the full ranking).

Where does 13F Pro source DSGN data?

All Design Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Design Therapeutics, Inc. files with the SEC under CIK 1807120. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is DSGN in?

Design Therapeutics, Inc. (DSGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is DSGN research updated on 13F Pro?

DSGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Design Therapeutics, Inc.(DSGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1807120 DSGN stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

DSGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Design Therapeutics, Inc. (DSGN), a Healthcare sector company. DSGN is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Design Therapeutics, Inc. reports net income of $-17.6M, free cash flow of $-16.4M. Top institutional holders of DSGN by reported 13-F value include SR ONE CAPITAL MANAGEMENT,, RA CAPITAL MANAGEMENT, L.P., Point72 Asset Management, L.P., based on the most recent SEC filings. DSGN trades on the Nasdaq exchange and files with the SEC under CIK 1807120. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DSGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Design Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-17.6M

Free Cash Flow

Q1 2026

$-16.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

$0.00FY 2025

FY22 —FY23 —FY24 $0.00FY25 $0.00

Net Income

-40.7% YoY

$-69.8MFY 2025

FY22 $-63.3MFY23 $-66.9MFY24 $-49.6MFY25 $-69.8M

Operating Income

-27.4% YoY

$-79.5MFY 2025

FY22 $-67.6MFY23 $-78.2MFY24 $-62.4MFY25 $-79.5M

EPS (Diluted)

-38.6% YoY

$-1.22FY 2025

FY22 $-1.14FY23 $-1.19FY24 $-0.88FY25 $-1.22

Total Assets

-10.3% YoY

$226.2MFY 2025

FY22 $341.1MFY23 $289.6MFY24 $252.1MFY25 $226.2M

Op. Cash Flow

-26.1% YoY

$-54.4MFY 2025

FY22 $-51.3MFY23 $-58.6MFY24 $-43.1MFY25 $-54.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00	$0.00	—	—	—	$226.0K
Net Income	$-69.8M -40.7%	$-49.6M +25.8%	$-66.9M -5.6%	$-63.3M -78.2%	$-35.5M -329.1%	$-8.3M
Operating Income	$-79.5M -27.4%	$-62.4M +20.2%	$-78.2M -15.7%	$-67.6M -88.6%	$-35.8M -330.1%	$-8.3M
EPS (Diluted)	$-1.22 -38.6%	$-0.88 +26.1%	$-1.19 -4.4%	$-1.14 -48.1%	$-0.77	—
Total Assets	$226.2M -10.3%	$252.1M -13.0%	$289.6M -15.1%	$341.1M -12.7%	$390.6M +969.6%	$36.5M
Operating Cash Flow	$-54.4M -26.1%	$-43.1M +26.4%	$-58.6M -14.1%	$-51.3M -74.7%	$-29.4M -238.9%	$-8.7M

AI Insight: DSGN Financial Trends

Design Therapeutics shows persistent pre-revenue burn with quarterly operating losses ranging from $15M to $22M across eight quarters.

• Operating losses deepened from $15M in Q2 2024 to $20M in Q1 2026.

• Cash burn improved modestly with operating cash flow recovering from $17M outflow in Q1 2025 to $16M in Q1 2026.

• Equity base declined from $261M in Q2 2024 to $218M in Q1 2026 as losses consumed capital.

⚠ Company remains pre-revenue with zero revenue across all eight quarters reported.

⚠ Equity recovered slightly to $218M in Q1 2026 from $200M low in Q3 2025, suggesting potential funding activity.

AI Insight: DSGN Ratio Trends

ROIC deteriorated from -23.0% in Q2 2024 to -36.1% in Q1 2026, reflecting worsening operational efficiency for this clinical-stage biotech.

• ROE declined from -18.1% in Q2 2024 to -32.4% in Q1 2026, showing deteriorating shareholder returns.

• ROA fell from -17.5% in Q2 2024 to -30.6% in Q1 2026, indicating declining asset utilization efficiency.

• ROIC contracted from -23.0% in Q2 2024 to -36.1% in Q1 2026, signaling worsening capital efficiency.

⚠ ROE improved from -35.8% in Q2 2025 to -32.4% in Q1 2026, suggesting potential stabilization.

⚠ All profitability metrics remain deeply negative, typical for clinical-stage biotech but concerning if sustained.

Get alerted when DSGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Design Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of DSGN

SR ONE CAPITAL MANAGEMENT, LP
$69.4M6,526,476 sh
RA CAPITAL MANAGEMENT, L.P.
$31.6M2,972,973 sh
Point72 Asset Management, L.P.
$29.0M2,722,754 sh
BAKER BROS. ADVISORS LP
$27.5M2,585,978 sh
BlackRock, Inc.
$22.7M2,133,764 sh
Logos Global Management LP
$20.7M1,950,000 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$18.6M1,744,987 sh
Vivo Capital, LLC
$17.2M1,612,903 sh
Almitas Capital LLC
$16.3M1,530,335 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.4M1,349,850 sh

Fund	Value	Shares
SR ONE CAPITAL MANAGEMENT, LP	$69.4M	6,526,476
RA CAPITAL MANAGEMENT, L.P.	$31.6M	2,972,973
Point72 Asset Management, L.P.	$29.0M	2,722,754
BAKER BROS. ADVISORS LP	$27.5M	2,585,978
BlackRock, Inc.	$22.7M	2,133,764
Logos Global Management LP	$20.7M	1,950,000
DRIEHAUS CAPITAL MANAGEMENT LLC	$18.6M	1,744,987
Vivo Capital, LLC	$17.2M	1,612,903
Almitas Capital LLC	$16.3M	1,530,335
VANGUARD CAPITAL MANAGEMENT LLC	$14.4M	1,349,850

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put DSGN on your watchlist

Track score changes the day Design Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is DSGN a good stock to buy?

13F Pro's AI-powered analysis of Design Therapeutics, Inc. (DSGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DSGN are available on the DSGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own DSGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DSGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Design Therapeutics, Inc.'s investment landscape.